Table 4.
Overview of ongoing oncology trials of agents targeting PDGFR or FGFR signaling.a
| Agent (type; target) | Trial description | Identifier number (status)b |
|---|---|---|
| PDGFR-targeted agents | ||
| IMC-3G3 (Ab: PDGFR-α) | Phase II trial of IMC-3G3 in combination with paclitaxel/carboplatin in previously untreated patients with advanced NSCLC | NCT00918203 (Recruiting) |
| Phase II trial of liposomal doxorubicin with or without IMC-3G3 in platinum-refractory or platinum-resistant advanced ovarian cancer | NCT00913835 (Active, no longer recruiting) | |
| Phase II trial of ramucirumab or IMC-3G3 in patients with glioblastoma multiforme | NCT00895180 (Recruiting) | |
| Phase II trial of IMC-3G3 in prostate cancer | NCT01204710 (Recruiting) | |
| Phase I/II trial of IMC-3G3 in soft tissue sarcomas | NCT01185964 (Recruiting) | |
| Phase I trial of safety and pharmacokinetics of IMC-3G3 in Japanese patients with solid tumors | NCT01199822 (Active, no longer recruiting) | |
| MEDI-575 (Ab: PDGFR-α) | Phase I trial evaluating dose escalation and dose expansion of MEDI-575 in patients with advanced cancer | NCT00816400 (Active, no longer recruiting) |
| Phase I trial of MEDI-575 in patients with advanced solid malignancies | NCT01102400 (Recruiting) | |
| Phase I/II trial of MEDI-575 in combination with paclitaxel/carboplatin in previously untreated patients with advanced NSCLC | NCT01268059 (Recruiting) | |
| Phase II trial of MEDI-575 in patients with recurrent glioblastoma multiforme | NCT01268566 (Recruiting) | |
| SU101 (small molecule: PDGFR) | Phase II trial of leflunomide (SU101) in patients with relapsed anaplastic astrocytoma | NCT00003775 (Unknown) |
| FGFR-targeted agents | ||
| BGJ398 (TKI: FGFRs) | Phase I dose escalation study in patients with advanced solid malignancies | NCT01004224 (Recruiting) |
| AZD4547 (TKI: FGFR) | Phase I dose escalation study in patients with advanced tumors | NCT00979134 (Recruiting) |
| Phase I/II trial of AZD4547 in combination with exemestane in estrogen receptor-positive breast cancer | NCT01202591 (Recruiting) | |
| Phase I trial of AZD4547 in Japanese patients with advanced solid malignancies | NCT01213160 (Recruiting) | |
a
Based on ClinicalTrials.gov accessed on March 22, 2011, with updates based on status as of November 15, 2011.
b
Active status indicates the trial is ongoing, but no longer recruiting patients.
Ab, antibody; FGFR, fibroblast growth factor receptor; PDGFR, platelet-derived growth factor receptor; TKI, tyrosine kinase inhibitor.